top of page

Gadolinium Deposition Disease
(GDD)

Defining GDD

GDD is a term to describe a collection of symptoms affecting multiple body systems that can result from receiving a GBCA injection during an MRI. Initial symptoms typically show immediately to a few weeks after the injection. Gadolinium is retained in the body.

Female patient undergoing MRI - Magnetic
GDD: About

Dr. Semelka's Discussions on GDD

Dr. Semelka's Discussions on GDD

Dr. Semelka's Discussions on GDD
Search video...
Episode #203: Gadolinium Deposition Disease with Dr. Richard Semelka, MD

Episode #203: Gadolinium Deposition Disease with Dr. Richard Semelka, MD

02:11:37
Play Video
183: Resiliency Radio with Dr. Jill:  Dr. Richard Semelka on Gadolinium Toxicity

183: Resiliency Radio with Dr. Jill: Dr. Richard Semelka on Gadolinium Toxicity

59:46
Play Video
Question & Answer with Gadolinium Expert Dr. Richard Semelka

Question & Answer with Gadolinium Expert Dr. Richard Semelka

01:04:47
Play Video
Discussing GDD with Dr. Martha Grout of AZ Integrative Medical Association

Discussing GDD with Dr. Martha Grout of AZ Integrative Medical Association

01:11:10
Play Video

Classic GDD Symptoms

You may have GDD if you experience several of the main symptoms listed below:

Central Nervous System

Head pain
Brain fog
Headaches
Tingling sensations
 
Muscle vibrations and fasciculations 
Skin pins and needles
Vibrations in arms and legs
Vision loss

Blurry vision
Tinnitus

Musculoskeletal System

Deep bone pain
Severe joint pain
Loss of mobility
Muscle loss

Increased weakness 
Fatigue

Dermatologic System

Skin discoloration
Skin substrate thickening 
Skin burning sensation 
Rashes

GDD: List

GDD Treatment

Dr. Semelka treats GDD patients in Chapel Hill, North Carolina with DTPA IV chelation treatments and FRAME drug protocol. For more information, please book a consultation with Dr. Semelka, and/or find more detailed treatment information on Dr. Semelka's blog.

gaddoc.jpg
GDD: About
Two Syringes

Dr. Semelka's Latest Article on GDD Near-Cure in Patients Undergoing IV DTPA Treatment

bottom of page